Loading provider…
Loading provider…
Hematology & Oncology Physician in Raleigh, NC
NPI: 1144497553Primary Practice Location
DUKE UNIVERSITY HOSPITAL
2301 Erwin Rd, Durham, NC
Primary Employer
Duke Health Integrated Practice, Inc.
dhip.dukehealth.org
HQ Phone
Get M.D. Danielle's Phone Numberphone_androidMobile
Get M.D. Danielle's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNC State Medical License
NC State Medical License
2007 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
Duke University School Of Medicine
medschool.duke.edu
Medical School
Until 2007
Duke University Hospital
Fellowship • Hematology and Medical Oncology
2010 - 2013
Residency • Internal Medicine
2007 - 2010
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 137 | 308 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 66 | 86 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 31 | 121 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 17 | 17 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 11 | 11 |
Authors: Wei Ding, Allison Rosenthal, Muhamad Alhaj Moustafa, Scott Huntington, Jose Leis, Han Tun, Stephen Schuster, Madiha Iqbal
Journal: Am J Hematol
Publication Date: 2023-03-07
SET Alpha and SET Beta mRNA Isoforms in Chronic Lymphocytic Leukaemia
Authors: Kebede Begna, Alexey Danilov, Yesid Alvarado Valero, Daniel Egan, Patrick Morgante, Rachel Cook, Vijaya Bhatt, Matthew Davids, Sameem Abedin
Journal: Blood Adv
Lead Sponsor: Zhejiang DTRM Biopharma
Intervention / Treatment: DRUG: DTRM-555
Lead Sponsor: Zhejiang DTRM Biopharma
Intervention / Treatment: DRUG: DTRM-555, DRUG: DTRMWXHS-12, DRUG: DTRM-505
Lead Sponsor: Sumitomo Pharma America, Inc.
Intervention / Treatment: DRUG: TP-0903, COMBINATION_PRODUCT: TP-0903 and ibrutinib combination therapy